PI3K inhibition to overcome endocrine resistance in breast cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108. PubMed PMID: 25651787; eng.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747–752. PubMed PMID: 10963602; eng.
   PubMed Web of Science ®Google Scholar
• Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. PubMed PMID: 22010023 J Clin Oncol. 2011;29(33):4452–4461.
   PubMed Web of Science ®Google Scholar
• Miller TW, Hennessy BT, González-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer. J Clin Invest. 2010;120(7):2406–2413. 06/07, 11/05/received, 04/14/accepted.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Fumagalli D, Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. Curr Opin Oncol. 2012 Nov;24(6):623–634. PubMed PMID: 22960556; eng.
   PubMed Web of Science ®Google Scholar
• Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):1950–1954.
   PubMed Web of Science ®Google Scholar
• Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002 Feb 2;2:101–112.
   PubMed Web of Science ®Google Scholar
• Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: erbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100(15):8933–8938. 07 09/12/17/received.
   PubMed Web of Science ®Google Scholar
• Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000 Dec 11;19(53):6102–6114. PubMed PMID: 11156523; eng.
   PubMed Web of Science ®Google Scholar
• Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):142–153. PubMed PMID: 12529347; eng.
   PubMed Web of Science ®Google Scholar
• Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. PubMed PMID: 17611206. New England J Med. 2007;357(1):39–51.
   PubMed Web of Science ®Google Scholar
• Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-Cancer Drugs. 2012;23(8):765–776.
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 1;28(1):92–98. PubMed PMID: 19933921; eng.
   PubMed Web of Science ®Google Scholar
• Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.
   Web of Science ®Google Scholar
• Bender LM, Nahta R. HER2 cross talk and therapeutic resistance in breast cancer. Frontiers Biosci: J Virtual Library 2008. 05/01;13:3906-3912. PubMed PMID: PMC2746389.
   Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13. DOI:10.1016/s1470-2045(11)70336-9
   Web of Science ®Google Scholar
• Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol: Off J Eur Soc Med Oncol. 2013 Nov;24(11):2715–2724. PubMed PMID: 23908178; eng.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. PubMed PMID: PMC3656649.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [10.1038/nrg1879]. Nat Rev Genet. 2006;7(8): 606–619. 08//print.
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–1657.
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis [10.1038/nrc1819]. Nat Rev Cancer. 2006;6(3):184–192. 03//print.
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. PubMed PMID: 20085938. J Clin Oncol. 2010;28(6):1075–1083.
   PubMed Web of Science ®Google Scholar
• Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci. 1999;96(8):4240–4245.
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8. DOI:10.1038/nrd2926
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations [10.1038/nrc2664]. Nat Rev Cancer. 2009;9(8): 550–562. 08 print.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005 Dec 4;12:988–1004. PubMed PMID: 16341064; eng.
   PubMed Web of Science ®Google Scholar
• Rexer BN, Arteaga CL. Optimal targeting of HER2–PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res. 2013;73(13):3817–3820.
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008 Aug 01;68(15):6084–6091. PubMed PMID: 18676830; PubMed Central PMCID: PMCPmc2680495. eng.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
   PubMed Web of Science ®Google Scholar
• Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004 Nov 01;64(21):7678–7681. PubMed PMID: 15520168; eng.
   PubMed Web of Science ®Google Scholar
• Network CGA. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490(7418):61.
   PubMed Web of Science ®Google Scholar
• Crowder RJ, Phommaly C, Tao Y, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor–positive breast cancer. Cancer Res. 2009;69(9):3955–3962.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013 Apr;71(4):829–842. PubMed PMID: 23377372; eng.
   PubMed Web of Science ®Google Scholar
• West KA, Castillo SS, Dennis PA Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2002 Dec;5( 6):234–248. PubMed PMID: 12531180; eng.
   Google Scholar
• Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007 10 16;12(4):395–402.
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 May 29;273(22):13375–13378. PubMed PMID: 9593664; eng.
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, De La Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998 Oct 02;95(1):29–39. PubMed PMID: 9778245; eng.
   PubMed Web of Science ®Google Scholar
• Sun H, Lesche R, Li D-M, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proceedings of the National Academy of Sciences of the United States of America; 1999 10 26; received 03/29/accepted;96( 11):6199–6204. PubMed PMID: PMC26859.
   Google Scholar
• Yap TA, Bjerke L, Clarke PA, et al. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015 8;23:98–107.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New England J Med. 2012;366(6):520–529. PubMed PMID: 22149876.
   PubMed Web of Science ®Google Scholar
• Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer [journal article]. Breast Cancer Res. 2011;13(2):R21.
   PubMed Web of Science ®Google Scholar
• Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015;7(283):283ra51–283ra51. PubMed PMID: PMC4433148.
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012 Feb;11(2):317–328. PubMed PMID: 22188813; eng.
   PubMed Web of Science ®Google Scholar
• Miller TW, Balko JM, Fox EM, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011 Sep 1;4:338–351. PubMed PMID: 22049316; PubMed Central PMCID: PMCPmc3204388. eng.
   Google Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–290. PubMed PMID: 22162589.
   PubMed Web of Science ®Google Scholar
• Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20;32(12):1202–1209. PubMed PMID: 24663045; PubMed Central PMCID: PMCPmc3986383. eng.
   PubMed Web of Science ®Google Scholar
• Pistilli B, Urruticoechea A, Stephen C, et al. Ph Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2+ advanced breast cancer. Ann Oncol. 2012;23(supplément 9):ix116.
   Google Scholar
• Loibl S, De La Pena L, Nekljudova V, et al., editors. Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer–neoPHOEBE. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-01.
   Google Scholar
• Gonçalves A, Guerin M, Isambert N, et al. Abstract A118: PIKHER2: a phase Ib study evaluating oral BKM120 in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. AACR; 2015.
   Google Scholar
• Martín M, Chan A, Dirix L, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer (BELLE-4). Ann Oncol. 2017;28(2):313–320.
   PubMed Web of Science ®Google Scholar
• Ma CX, Luo J, Naughton M, et al. A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer. Clin Cancer Res. 2015. DOI:10.1158/1078-0432.ccr-15-1745
   Web of Science ®Google Scholar
• Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904–916. PubMed PMID: 28576675; PubMed Central PMCID: PMCPmc5549667. eng.
   PubMed Web of Science ®Google Scholar
• Baselga J, Im S, Iwata H, editors. BELLE-2: phase III, randomized, placebo-controlled study of buparlisib with fulvestrant in postmenopausal women with HR+/HER2-advanced breast cancer progressive on or after an aromatase inhibitor. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 6–10, 2015. Abstract S6–01.
   Google Scholar
• Bandaru SS, Lin K, Roming SL, et al. Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol Behav. 2010;100(3):239–244.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Lee KS, Ciruelos E, et al. Abstract S4-07: BELLE-3: a phase III study of buparlisib+ fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. AACR; 2017.
   Google Scholar
• Schmid P, Pinder SE, Wheatley D, et al. Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor–positive breast cancer. J Clin Oncol. 2016;34(17):1987–1994. PubMed PMID: 26976426..
   PubMed Web of Science ®Google Scholar
• Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(6):811–821.
   PubMed Web of Science ®Google Scholar
• Vuylsteke P, Huizing M, Petrakova K, et al. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann Oncol. 2016;27:2059-2066.
   Web of Science ®Google Scholar
• Zhao JJ, Cheng H, Jia S, et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America. 2006 10 23 08/15/received;103( 44):16296–16300. doi: 10.1073/pnas.0607899103. PubMed PMID: PMC1637576.
   Google Scholar
• Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110[bgr] in cell growth, metabolism and tumorigenesis [10.1038/nature07091]. Nature. 2008 08 07;454(7205):776–779. print: http://www.nature.com/nature/journal/v454/n7205/suppinfo/nature07091_S1.html
   PubMed Web of Science ®Google Scholar
• Edgar KA, Wallin JJ, Berry M, et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors [10.1158/0008-5472.CAN-09-2525]. Cancer Res. 2010;70(3):1164.
   PubMed Web of Science ®Google Scholar
• Fritsch C, Huang A, Chatenay-Rivauday C, et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117–1129. PubMed PMID: 24608574; eng.
   PubMed Web of Science ®Google Scholar
• Mayer IA, Abramson VG, Formisano L, et al. A phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2− metastatic breast cancer. Clin Cancer Res. 2017;23(1):26–34.
   PubMed Web of Science ®Google Scholar
• Janku F, Juric D, Cortes J, et al. Abstract PD5-5: phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer. AACR; 2015.
   Google Scholar
• Andre F, Campone M, Ciruelos EM, et al. SOLAR-1: a phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy. J Clin Oncol. 2016;34(15_suppl):TPS618–TPS618.
   Web of Science ®Google Scholar
• Friedman L, Edgar K, Song K, et al. Abstract S6-04: the PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action. AACR; 2017.
   Google Scholar
• Juric D, Krop I, Ramanathan RK, et al. Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. In: Cancer discovery. 2017;7(7):704-715. doi: 10.1158/2159-8290.cd-16-1080.
   Google Scholar
• Dickler MN, Saura C, Richards DA, et al. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). Am Soc Clin Oncol. 2016;34(15_suppl):520-520. doi: 10.1200/JCO.2016.34.15_suppl.520.
   Web of Science ®Google Scholar
• Baselga J, Cortes Castan J, De Laurentiis M, et al. SANDPIPER: phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours. Journal of Clinical Oncology. 2017;35(15_suppl):TPS1119-TPS1119. doi: 10.1200/JCO.2017.35.15_suppl.TPS1119.
   Google Scholar
• Azambuja ED, Saura C, Oliveira M, et al. LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. Am Soc Clin Oncol. 2015;33(15_suppl):TPS627-TPS627. doi: 10.1200/jco.2015.33.15_suppl.tps627.
   Google Scholar
• Saura C, Azambuja ED, Oliveira M, et al. LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. Am Soc Clin Oncol. 2016;34(15_suppl):TPS613-TPS613. doi: 10.1200/JCO.2016.34.15_suppl.TPS613.
   Google Scholar
• Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62(14):4132–4141.
   PubMed Web of Science ®Google Scholar
• Loibl S, Majewski I, Guarneri V, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol: off J Eur Soc Med Oncol. 2016 Aug;27(8):1519–1525. PubMed PMID: 27177864; eng.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Lambrechts D, et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst. 2013 Jul 03;105(13):960–967. PubMed PMID: 23739063; PubMed Central PMCID: PMCPmc3699437. eng.
   PubMedGoogle Scholar
• Elster N, Cremona M, Morgan C, et al. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Breast Cancer Res Treat. 2015;149(2):373–383.
   PubMed Web of Science ®Google Scholar
• Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20(7):1935–1945.
   PubMed Web of Science ®Google Scholar
• Tolaney S, Burris H, Gartner E, et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2015;149(1):151–161.
   PubMed Web of Science ®Google Scholar
• Loibl S, De La Pena L, Nekljudova V, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer. Oxford, England: 1990 2017 Nov;85:133–145. PubMed PMID: 28923573; PubMed Central PMCID: PMCPmc5640494. eng.
   PubMed Web of Science ®Google Scholar
• Shah RR. Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity? Drug Saf. 2017 03;40(3):211–228. PubMed PMID: 27981444; eng.
   PubMed Web of Science ®Google Scholar
• Crouthamel M-C, Kahana JA, Korenchuk S, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res. 2009;15(1):217–225.
   PubMed Web of Science ®Google Scholar
• Foukas LC, Claret M, Pearce W, et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature. 2006;441(7091):366–370.
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell. 2006;125(4):733–747.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. In: Clinical Cancer Research. Philadelphia:AACR. 2014;20(1):233-245. doi: 10.1158/1078-0432.ccr-13-1777.
   Google Scholar
• Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11(8):2875–2878.
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2004 12 20;24(8):1477–1480. online.
   Web of Science ®Google Scholar
• Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22(21):3205–3212.
   PubMed Web of Science ®Google Scholar
• Liang K, Jin W, Knuefermann C, et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy1. Mol Cancer Ther. 2003;2(4):353–360.
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation [10.1038/nrc1753]. Nat Rev Cancer. 2005 12;5(12):921–929. print.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15. DOI:10.1158/1078-0432.ccr-09-0632
   PubMed Web of Science ®Google Scholar
• Sabine VS, Crozier C, Brookes CL, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol. 2014;32(27):2951–2958.
   PubMed Web of Science ®Google Scholar
• Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2010 Jul;122(1):45–53. PubMed PMID: 19701705; eng.
   PubMed Web of Science ®Google Scholar
• Ligresti G, Militello L, Steelman LS, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle. 2009;8(9):1352–1358.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005 Dec 01;65(23):10992–11000. PubMed PMID: 16322248; eng.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Liu Z, Wang L, et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443–18448. PubMed PMID: 16339315; PubMed Central PMCID: PMCPmc1317954. eng.
   PubMed Web of Science ®Google Scholar
• Pang B, Cheng S, Sun S-P, et al. Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis Scientific reports; Springer Nature. 2014. p. 4.
   Google Scholar
• Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011 Feb 15;17(4):667–677. PubMed PMID: 20940279; eng.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011 Jun;10(6):1093–1101. PubMed PMID: 21490305; PubMed Central PMCID: PMCPmc3112276. eng.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Favero F, De Bruin EC, et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015;7(283):283ra54–283ra54.
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18(12):3462–3469.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Chen D, Piccart M, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2015;34(5):419–426.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Chen D, He W, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116(6):726–730.
   PubMed Web of Science ®Google Scholar
• André F, Hurvitz S, Fasolo A, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2–overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 2016;34(18):2115–2124.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New England J Med. 2014;371(20):1877–1888.
   PubMed Web of Science ®Google Scholar
• Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 2012;17(3–4):205–216.
   PubMed Web of Science ®Google Scholar
• Sun S-Y, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65(16):7052–7058.
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66. DOI:10.1158/0008-5472.can-05-2925
   Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68. DOI:10.1158/0008-5472.can-08-1385
   Web of Science ®Google Scholar
• Wise-Draper TM, Moorthy G, Salkeni MA, et al. A phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target Oncol. 2017 03 29;12(3):323–332. PubMed PMID: PMC5447332.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Wesolowski R, Bardia A, et al. Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032). J Clin Oncol. 2017;35(15_suppl):TPS1113–TPS1113.
   Google Scholar
• Ma CX, Reinert T, Chmielewska I, et al. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15(5):261–275.
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26(1):136–149.
   PubMed Web of Science ®Google Scholar
• Sos ML, Fischer S, Ullrich R, et al. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci. 2009;106(43):18351–18356.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–1356.
   PubMed Web of Science ®Google Scholar